Literature DB >> 5015038

Investigations of the mode of action of a new antidysrhythmic drug, Kö 1173.

B N Singh, E M Vaughan Williams.   

Abstract

1. Kö 1173, 1-(2',6'-dimethyl-phenoxy)-2-amino-propane, was equal to lignocaine in potency as a local anaesthetic on stripped frog sciatic nerve at pH 7.5.2. In anaesthetized guinea-pigs in which ventricular fibrillation had been produced by an intravenous infusion of ouabain, intravenous administration of Kö 1173 caused reversion to sinus rhythm in ten out of ten animals. The mean dose of Kö 1173 required was 3.3 mg (15.3 mumol)/kg. When the ouabain infusion was continued, ventricular fibrillation did not recur, and the lethal dose of ouabain was greater than in controls.3. Pretreatment with Kö 1173, however, did not influence the toxicity of ouabain infusion, implying great brevity of action.4. Kö 1173 given intravenously caused a bradycardia which was maximal in 2-3 min, and which did not last more than 5 minutes.5. Kö 1173 reduced the maximum driven frequency of isolated rabbit atria, raised electrical threshold, slowed conduction velocity and depressed contractions.6. Kö 1173 reduced the maximum rate of depolarization of intracellularly recorded rabbit atrial and ventricular potentials, but did not affect the resting potential or the duration of the action potential.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5015038      PMCID: PMC1665694          DOI: 10.1111/j.1476-5381.1972.tb07232.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Prevention of arrhythmias due to cardiac glycosides by block of sympathetic beta receptors.

Authors:  E M WILLIAMS; A SEKIYA
Journal:  Lancet       Date:  1963-02-23       Impact factor: 79.321

2.  The effect of changes in extracellular potassium concentration on the intracellular potentials of isolated rabbit atria.

Authors:  E M VAUGHAN WILLIAMS
Journal:  J Physiol       Date:  1959-06-11       Impact factor: 5.182

3.  Antifibrillatory action.

Authors:  L Szekeres; E M Williams
Journal:  J Physiol       Date:  1962-03       Impact factor: 5.182

4.  The effect of experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide.

Authors:  J D Allen; J M Kofi; R G Shanks; S A Zaidi
Journal:  Br J Pharmacol       Date:  1970-05       Impact factor: 8.739

5.  Effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle.

Authors:  B N Singh; E M Williams
Journal:  Circ Res       Date:  1971-09       Impact factor: 17.367

6.  Electrophysiological effects of diphenylhydantoin on canine purkinje fibers.

Authors:  J T Bigger; A L Bassett; B F Hoffman
Journal:  Circ Res       Date:  1968-02       Impact factor: 17.367

7.  Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects.

Authors:  J T Bigger; D H Schmidt; H Kutt
Journal:  Circulation       Date:  1968-08       Impact factor: 29.690

8.  Current status of diphenylhydantoin.

Authors:  L S Dreifus; Y Watanabe
Journal:  Am Heart J       Date:  1970-11       Impact factor: 4.749

9.  The mode of action of quinidine on isolated rabbit atria interpreted from intracellular potential records.

Authors:  E M VAUGHAN WILLIAMS
Journal:  Br J Pharmacol Chemother       Date:  1958-09

10.  The relevance of beta-receptor blockade to ouabain-induced cardiac arrhythmias.

Authors:  A N Dohadwalla; A S Freedberg; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1969-06       Impact factor: 8.739

  10 in total
  11 in total

1.  Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.

Authors:  Rayomand J Unwalla; Jason B Cross; Sumeet Salaniwal; Adam D Shilling; Louis Leung; John Kao; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2010-04-02       Impact factor: 3.686

Review 2.  [Electrophysiological classification of newer antiarrhythmic drugs (author's transl)].

Authors:  W Schmitz
Journal:  Klin Wochenschr       Date:  1980-09-15

Review 3.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

4.  [Mexiletine--findings in animal experiments on its antiarrhythmic and electrophysiological effects in the heart (author's transl)].

Authors:  K Haap; H Antoni
Journal:  Klin Wochenschr       Date:  1978-02-15

5.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

6.  An unusual cause of apparent epilepsy: ECG and EEG findings in a case of Jervell Lange-Neilson syndrome.

Authors:  P J Selby; M V Driver
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-11       Impact factor: 10.154

Review 7.  Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.

Authors:  C Y Chew; J Collett; B N Singh
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

8.  Efficacy of oral mexiletine in the prevention of exercise-induced ventricular ectopic activity.

Authors:  G Koch; B Lindström
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

Review 9.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  Effects of mexiletine on delayed after-depolarization and triggered activity.

Authors:  H Uchida; E Ozawa; Y Watanabe
Journal:  Heart Vessels       Date:  1990       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.